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ARTICLE OPEN
Lung cancer patients’ comorbidities and attendance of German
ambulatory physicians in a 5-year cross-sectional study
Jasmin Bossert 1✉, Marion Ludwig 2, Pamela Wronski 1, Jan Koetsenruijter 1, Katja Krug 1, Matthias Villalobos3,
Josephine Jacob 2, Jochen Walker2, Michael Thomas3 and Michel Wensing1
The majority of lung cancer patients are diagnosed with an advanced stage IV, which has short survival time. Many lung cancer
patients have comorbidities, which influence treatment and patients’ quality of life. The aim of the study is to describe
comorbidities in incident lung cancer patients and explore their attendance of ambulatory care physicians in Germany. In the
observed period, 13,111 persons were first diagnosed with lung cancer (1-year incidence of 36.4 per 100,000). The mean number of
comorbidities over 4 quarters was 30.77 ± 13.18; mean Charlson Comorbidity Index was 6.66 ± 2.24. In Germany, ambulatory care
physicians most attended were general practitioners (2.6 quarters with contact within 4 quarters). Lung cancer was diagnosed by a
general practitioner in 38% of the 13,111 incident patients. The average number of ambulatory care physician contacts over 4
quarters was 35.82 ± 27.31. High numbers of comorbidities and contacts in ambulatory care are common in patients with lung
cancer. Therefore, a cross-sectoral and interdisciplinary approach is required for effective, patient-centred care. This was a 5-year
cross-sectoral study, based on the InGef research database, which covers anonymized health insurance data of 7.2 million
individuals in Germany. Incident lung cancer patients in a 5-year period (2013–2017) were identified. Descriptive statistics were
calculated for sociodemographic characteristics, comorbidities, and attendance of ambulatory care physicians.
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INTRODUCTION
Despite improved diagnostic and treatment options, lung cancer
remains one of the most malignant diseases and the leading cause
of cancer-related deaths worldwide1. The majority of lung cancer
patients (about 70%) are diagnosed with an advanced stage IV
disease, which is characterized by short survival time in comparison
with other cancer diseases (the 5-year survival in Europe is <20%)2.
Comorbidities seem to influence cancer prognosis survival in various
ways3. The prevalence of comorbidity increases with age4. Due to
the fact that lung cancer is most frequent in men in the age of
80–84 years and women in the age of 70–74 years, consideration of
comorbidities during treatment planning should receive more
attention5. Most clinical guidelines of cancer treatment do not
reflect the complex inter-relation between cancer and comorbidity
but instead pursue a “single disease” approach in management6.
Nevertheless, diseases that existed before cancer diagnosis have an
effect on the risks and outcomes of cancer treatments, both in
cancer in general and specifically in lung cancer7,8. Therefore, data
on comorbidities, along with patient demographics, is essential for
comprehensive treatment and care in lung cancer. Such data are
required to enhance clinical decision-making and supportive tools,
as well as the design and planning of healthcare services for patients
with lung cancer6,8,9.
With the growing complexity in the treatment of cancer and
comorbidities, cross-sectoral and interdisciplinary coordinated
patient care has become the preferred model in health care10.
In many situations, it is necessary to set priorities in the treatment
and care of different diseases of a patient, which requires effective
cooperation between providers in different healthcare settings11.
Furthermore, it offers patients the possibility to get a balanced
perspective on the risks and benefits of all available treatment
options during treatment decision, thus strengthening prognostic
awareness. To reach effective cross-sectoral cooperation, current
data on the prevalence of comorbidities and the contacts with
various healthcare providers involved is required12.
To our knowledge, there are no studies in Germany that
document comorbidities in lung cancer patients and the attendance
of ambulatory care physicians involved in the treatment for lung
cancer patients. The aim of the present study was to describe the
comorbidities in newly diagnosed lung cancer patients in Germany
and explore the physicians they consulted in ambulatory care.
RESULTS
Prevalence
Out of the sample of 4.9 million patients, 3,275,709 were
constantly insured (with the insurers linked to the database),
and of these, 20,802 persons (mean age 70 years) had the
diagnosis lung cancer in the period 2013–2017. This corresponds
to a 5-year prevalence rate of 635 persons per 100,000 inhabitants
with 1-year prevalence rates between 206.6 (year 2013) and 227.8
(year 2016) per 100,000 persons. Supplementary Table 1 presents
an overview of prevalent cases from 2013 to 2017.
Study population (incident cases)
In the period 2013–2017, 13,111 persons (mean age 70 years)
were newly diagnosed with lung cancer. Numbers varied per year
between 2649 and 2826 patients corresponding to incidence rates
of 69.1 (95% confidence interval (CI) 66.45–71.73) and 76.6 (95% CI
73.84–79.52) per 100,000 persons (Table 1). More men (n= 8301;
63.31%) than women (n= 4810; 36.69%) were affected (Table 2).
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For the purposes of healthcare services research, a sample of
approximately 4 million patients per year was selected, which is
representative of the German population regarding age and sex.
Projected to the total German population, an estimated
57,070–62,135 persons per year was diagnosed with lung cancer
between 2013 and 2017.
Comorbidities
Essential (primary) hypertension was the most frequent comor-
bidity of incident lung cancer patients in Germany (74.3%) without
substantial differences between the different federal states (range:
62.8–84.4%) (Supplementary Table 2). The second most frequent
comorbidity in Germany was “disorders of lipoprotein metabolism
and other lipidomes” (51.4%) followed by “other chronic
obstructive pulmonary diseases” (46.6%). In total, 1326 different
comorbidities were detected at the 3-digit level during the
observation period (patient-individual year). A comprehensive list
of the 100 most frequent comorbidities can be found in
Supplementary Table 3. The average number of comorbidities
(including all co-occurring diseases) within four quarters is higher
in women than in men and is highest in the age group >75 years
(women: 33.93 ± 13.88; men: 32.65 ± 13.35). In both sexes and in
all age groups, the Charlson Comorbidity Index (CCI) is about 6
(range: 6.09–6.97) (Table 3).
Table 1. Incidence of lung cancer (C34*).
Fully insured persons N N non-prevalent Cases/100,000 Lower 95% CI bound Upper 95% CI bound
N
2013 3,649,007 2660 3,643,814.00 73.00 70.25 75.83
2014 3,692,998 2826 3,687,290.00 76.64 73.84 79.52
2015 3,780,098 2810 3,774,074.00 74.46 71.73 77.26
2016 3,799,249 2832 3,793,060.00 74.66 71.94 77.46
2017 3,842,919 2649 3,836,387.00 69.05 66.45 71.73
2012–2017 3,129,423 13,111 3,122,023.00 419.95 412.81 427.19
Table 2. Incidence of lung cancer stratified by age and sex.
2013 2014 2015 2016 2017 2013–2017
N % N % N % N % N % N %
Incident patients
Number of patients 2660 100 2826 100 2810 100 2832 100 2649 100 13,111 100
<60 years 887 33.4 891 31.5 887 31.6 886 31.3 775 29.3 3095 23.6
60–75 years 1599 60.1 1751 62.0 1718 61.1 1746 61.7 1666 62.9 8528 65
>75 years 174 6.5 184 6.5 205 7.3 200 7.1 208 7.9 1488 11.4
Male
Number of patients 1710 100 1774 100 1817 100 1723 100 1646 100 8301 100
<60 years 499 29.2 490 27.6 523 28.8 474 27.5 438 26.6 1713 20.6
60–75 years 1099 64.3 1176 66.3 1165 64.1 1,125 65.3 1076 65.4 5629 67.8
>75 years 112 6.6 108 6.1 129 7.1 124 7.2 132 8 959 11.6
Female
Number of patients 950 100 1052 100 993 100 1109 100 1003 100 4810 100
<60 years 388 40.8 401 38.1 364 36.7 412 37.2 337 33.6 1382 28.7
60–75 years 500 52.6 575 54.7 553 55.7 621 56 590 58.8 2899 60.3
>75 years 62 6.5 76 7.2 76 7.7 76 6.9 76 7.6 529 11
Table 3. Average number of comorbidities and mean CCI score of





Mean SD Mean SD
Incident patients
All 30.77 13.17 6.66 2.24
<60 years 27.10 12.39 6.20 2.04
60–75 years 30.49 12.89 6.62 2.20
>75 years 33.06 13.54 6.96 2.35
Male
<60 years 26.42 12.45 6.29 2.06
60–75 years 30.14 12.73 6.70 2.24
>75 years 32.65 13.35 6.97 2.36
All 30.49 13.07 6.73 2.27
Female
<60 years 27.94 12.27 6.09 2.01
60–75 years 31.07 13.14 6.49 2.13
>75 years 33.93 13.88 6.95 2,35
All 31.26 13.34 6.54 2.19
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Both in Germany overall (mean= 2.6 contact quarters (CQs) within
4 patient-individual quarters) as well as in the individual German
federal states (mean= 2.4–2.8), the general practitioner was
contacted most frequently, followed by internists with an average
of 2.3 contact in Germany and an average ranging from 2.0 to 2.4
in the individual federal states. The ear, nose and throat specialists
(ENT) were contacted on average in 1.4 quarters (see also
Supplementary Table 4), which is linked to the most common
comorbidities of incident lung cancer patients (Supplementary
Table 2), as chronic obstructive pulmonary diseases and respira-
tory insufficiency are also treated by the ENT. Within the
observation period of four patient-individual quarters, the average
number of visits to ambulatory care physicians in incident lung
cancer patients was higher for women aged <60 years (45.08 ±
30.26) and women aged between 60 and 75 years (38.51 ± 27.30)
than for men in this age groups (40.38 ± 29.24/36.10 ± 27.06). In
the age group >75 years, it can be seen that men (31.57 ± 25.93)
had a slightly higher number of contacts with ambulatory care
physicians than women (28.60 ± 23.47) (Table 4).
Table 5 shows the specialists who first diagnosed lung cancer in
the outpatient sector. The analysis shows that the general
practitioner most often made the initial diagnosis in the
outpatient sector (38.1%). In 6.7% of all cases, the specialty of
the diagnosing physician was not registered. The majority of
patients seem not to be diagnosed in the outpatient sector but by
inpatient healthcare providers.
DISCUSSION
This study documented the number of incident lung cancer
patients in Germany and their most frequent and number of
comorbidities, the Charlson Comorbidity Index, contacts to
ambulatory care physicians, differences between federal states
and ambulatory care physicians who made the initial diagnosis of
lung cancer in Germany in incident lung cancer patients. Lung
cancer patients have many comorbidities (30.77 ± 13.18) and a
high CCI score, indicating major burden from multimorbidities.
Many of the most prevalent comorbidities are in the domain of
internal medicine. The specialist group most consulted by lung
cancer patients in ambulatory care is the general practitioner.
General practitioners also make the initial diagnosis most
frequently throughout Germany.
Data from the Robert-Koch-Institute (based on the population-
based cancer registry in Germany) also show that men (36,000) are
more frequently diagnosed with lung cancer than women
(21,500). This corresponds to a 1-year incidence rate for men of
88.6/100,000 and for women of 51.5/100,000, which is comparable
to our results. The prevalence rates found in this study are higher
than the official cancer registry data in Germany5. This could be
explained by the fact that only a limited number of statutory
health insurance (SHI) organizations were included in this analysis.
About 75% of the patients included in our study had at least one
comorbidity. The average number of comorbidities in incident lung
cancer patients was 30.77, measured over four patient-individual
quarters. However, it is important to note that each co-existing
disease is included in the analysis (including single-event diagnoses,
such as cystitis), which leads to the relatively high number of
average comorbidities over four quarters. The high number of
comorbidities can also be explained by the fact that the underlying
data structure of this study is very differentiated and uses the 3-digit
tenth revision of the International Classification of Diseases (ICD)-10
code with its highly specific breakdown of diseases of one organ.
For example, a given intestinal disease may have received two
different codes within a patient-specific year, which could have been
aggregated in other studies with a significantly lower number of
comorbidities13,14. Despite this fact, it is reasonable to assume that
the average number gives an indication that lung cancer patients
suffer from a disease burden that requires expertise from various
medical domains, even if not all included co-existing diseases
progress to a permanent diagnosis. On the other hand, the aspect of
death as an exit from the study sample has to be considered. Even if
the mortality of the included patients has not been analysed, it is still
important to keep this in mind with regard to the average number
of comorbidities. This might have reduced the average number of
comorbidities.
The most common comorbidity is essential primary hyperten-
sion. Studies show that the prevalence of essential primary
hypertension is nationwide on a high level, regardless of whether
an oncological diagnosis is available. The prevalence of hyperten-
sion increases with age. Almost two-thirds of Germans aged ≥65
years have a diagnosed hypertension15.
The number of CQs and the average number of visits to
ambulatory care physicians gives an estimate of the extent of
comorbidities requiring treatment. Studies show that the severity
of an illness affects the number of contacts with care physicians16.
Evidence from 2020 demonstrate that comorbidities in lung
cancer patients lead to >50% annual rise in the number of
contacts to ambulatory care physician. Furthermore, a German
study reflects that every additional comorbidity to an index
disease is associated with an increase by the factor of 2.3 in
Table 4. Average number visits to ambulatory care physicians.




<60 years 42.49 29.79
60–75 years 36.99 27.17
>75 years 30.62 25.21
Male
<60 years 40.38 29.24
60–75 years 36.10 27.06
>75 years 31.57 25.93
All 35.13 27.15
Female
<60 years 45.08 30.26
60–75 years 38.51 27.30
>75 years 28.60 23.47
All 37.01 27.54
Table 5. Specialists who first diagnosed lung cancer in the outpatient
sector.
Specialist group Patients (n) (%)
General practitioner 4995 38.1






ENT specialist 132 1.0
Nuclear medicine specialists 130 0.9
Radiologist 122 0.9
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medical contacts. Consequently, the number of comorbidities is
associated with a significant increase in physician contacts
compared to patients without comorbidity17. Considering that in
2007 the number of physician contacts for all statutory insured
people in Germany was 1718, the disease burden of patients with
lung cancer is underlined by the fact that they visited an
outpatient care provider 35 times and have a CCI about 6.
However, general practitioners and most other specialist groups
are not comprehensively skilled to manage the wide spectrum of
coexisting diseases in patients with cancer. Lung cancer patients
with comorbidities often need multimodal treatment and care,
delivered by different professionals, in different settings and at
different time points. In order to obtain complete information on
comorbidities, all involved specialist groups providing treatment
for lung cancer patients with comorbidities should be mutually
known6. At the same time, clinicians outside oncology (including
ambulatory care physicians) need to consider the impact of cancer
in their treatment decisions on comorbid diseases. This requires
effective cross-sectoral cooperation12. To achieve the goal of
cross-sectoral and multidisciplinary coordinated patient care, an
effective network of all specialists involved within one sector is a
precondition.
Within the network of cross-sectoral cooperation, current
evidence indicates that a coordinator should be appointed to
organize and priorities healthcare processes across service
sectors19,20. In this context, the general practitioner is usually the
first person to be contacted by patients with health problems and
is therefore conceivable in the role of a coordinator21. In addition,
the general practitioner is the care provider who generally has a
long-term relationship with patients, which is often intensified
following a cancer diagnosis22.
Furthermore, patients with advanced cancer often experience
prolonged and frequent hospital stays22. Between hospital stays,
patients are treated by outpatient specialists for both cancer and
comorbidities. Cooperation and effective networking of all
stakeholders, both within a sector and across sectors, supports
patient-centred care.
A conceivable approach to support cross-sectoral cooperation
could be the use of an electronic platform. The central access to
patient-relevant data facilitates the exchange between participat-
ing specialists and also has a positive impact on organizational
aspects, since the personal exchange of information is not
fundamental and can be reduced to special events in the
treatment context. In particular, general practitioners in their role
of the treatment coordinator could benefit from the use of
electronic tools such as the electronic patient record as they can
quickly and easily provide anamnestic information for other
treating specialists and receive information on activities from
other physicians. In this way the cooperation between the
participating service providers might be improved23. Considering
the average number of comorbidities, the CCI scores (>5), which
are associated with a high risk of death within the next year, and
the contacts to care providers, this aspect is gaining in relevance
and can help to improve patient safety. Treatment errors can be
avoided by providing comprehensive digital patient data for
healthcare providers, especially in emergency situations. Further-
more, there is a positive correlation between the electronic
recording of medication and patient adherence24.
Although the use of electronic patients’ records could be a
solution to overcome barriers in cross-sectoral healthcare, their
implementation is still a major challenge25. One of the reasons for
the difficulties in implementing telemedicine is the very restrictive
data protection laws in Germany. These guarantee a high level of
data security for patients but currently offer limited scope for
innovation26. An additional challenge in implementing e-health
across healthcare sectors is the interoperability of the currently
existing data systems. Accordingly, serious problems often arise
when integrating different electronic systems within the
outpatient and inpatient sector. To solve the problem, the
uncontrolled growth of different standard operating procedures
in the file systems should be eliminated. In addition to
interoperability as a central prerequisite for digitization, govern-
ment policy is seen as a relevant component. Therefore, it is the
task of politics to improve the necessary framework conditions for
the successful implementation of e-health in the healthcare
system to support healthcare across service sectors25. Further-
more, the users’ attitude towards e-health must be considered.
Therefore, the usability of new technologies is perceived as an
additional challenge by some individuals27.
In summary, treating patients with oncological diagnoses involves
consideration of their comorbidities, the involvement of other
treating specialists and their treatment approaches. It must be
aimed to develop a common therapy plan that reflects all the
existing diseases of a patient and is coordinated with all treating
physicians. The results obtained in this study serve as an indicator
for the treatment of lung cancer patients and justify the need for
collaborative treatment planning. The results of the analysis show
that lung cancer patients consult not only general practitioners but
also various other specialists (e.g. outpatient internists). Effective
cross-sectoral cooperation is seen as an improvement in patient
safety and health-related quality of life. Especially for diseases with a
limited prognosis, which are associated with a high risk of mortality
within the next year, the relevance of these aspects increases.
Comorbidities are frequent in patients with lung cancer, which
leads to the assumption that there is much potential for
improvement in coordination for the individual patient. Therefore,
a complete assessment of comorbidities and ambulatory care
physicians is needed for a holistic treatment approach and
contributes to patient-centred care. A cross-sectoral and inter-
disciplinary approach based on a uniform electronic platform is
recommended.
Limitations of this analysis include those inherent to claims
database studies, such as the reliance on accurate coding and
diagnosis. Consequently, results need to be interpreted cautiously.
In general, routine data are collected primarily for reimbursement
purposes and not for clinical research. For example, the data of
privately insured persons may differ from that of persons with SHI
organizations due to different reimbursement practices or with
regard to their socioeconomic status and therefore the general-
izability of the results obtained in this study may be limited28.
Nevertheless, the validity and comprehensiveness of German
health claims data can be considered very high. The fact that only
a limited number of SHI organizations were included in this
analysis could explain why the calculated prevalence rate of this
study shows large deviations to the prevalences according to the
official cancer registry data in Germany5.
METHODS
Study design
This study is a 5-year cross-sectoral study using claims-based data. The
observation period for identifying incident lung cancer patients was
01.01.2012–31.12.2017. Incident cases of lung cancer patients were
determined for a 5-year period (01.01.2013–31.12.2017 inclusion period;
01.01.2012–31.12.2012 additional lookback time) to report age, gender, the
ten most frequent comorbidities, the ten most involved ambulatory care
physicians, number of quarter years with contact to ambulatory care
physicians’ groups and differences between federal states in Germany.
Data source
We used data from the InGef (Institute for Applied Health Research Berlin
GmbH) research database. This database is an anonymized healthcare
claims database with longitudinal data from approximately 7.2 million
persons (8.67% of the German population), who are insured with one of
>60 German SHI organizations. Data since 2012 are available in this
database. For this study, a sample of 4.9 million patients from January 2013
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to December 2017 was drawn and adjusted for age and sex based on
official national statistics (Destatis, 31 December 2017).
All diagnoses in the database are coded according to the German
modification of the ICD-10 (ICD-10-GM). All patient-level data in the InGef
database are de-identified to comply with German data protection
regulations and German federal law. Hence, separate approval of an
institutional review board or Medical Ethics Committee was not required.
In brief, the database includes the following data: an anonymized
identification number, demographic data (age, sex, region of living), date
of death, periods of coverage for the health insurance, diagnoses
according to ICD-10-GM for ambulatory care and hospital data, including
admission and discharge date, procedures and diagnoses, prescription
data and specialty of the prescribing or diagnosing physician29.
Study population
Adult patients (≥18 years) were only included in the study population
(incident cases) if they were continuously insured during the observation
period at one of the SHI organization included in the InGef database.
Patients were included if they met the following inclusion criteria: A newly
assured diagnosis of ICD-10-GM C34* in the outpatient sector or main and
secondary diagnosis of ICD-10-GM C34* at discharge in the inpatient area.
A diagnosis was considered confirmed if the diagnosis ICD-10-GM C34* in
the outpatient sector was mentioned by two different physicians in the
index quarter (quarter of the initial diagnosis) or by the same physician in
two consecutive quarters. The unique diagnosis of ICD-10-GM C34* made
by providers of the inpatient sector was also regarded as a confirmed
diagnosis.
An incident lung cancer case entered the study sample at the moment
of the first diagnosis following a validation period of 4 quarters (2012) free
of lung cancer diagnoses to ensure that only incidences of lung cancer
were present. Re-entry into the study sample by the same patient was not
allowed. Study entry was at the beginning of the quarter in which lung
cancer diagnosis was first documented. Study exit was defined as death or
the end of the inclusion period (31.12.2017). There could also be incidence
patients in the study sample who died within the follow-up period. Of
note, these patients then contribute correspondingly less to the average
comorbidity or quarterly number of specialist visits.
Measures
The measures concerned comorbidities and involved ambulatory care
physicians in incident lung cancer patients.
Comorbidities were defined as confirmed outpatient diagnoses (3-digit)
and/or inpatient primary and/or secondary diagnoses (3-digit) according to
ICD-10-GM. The classifications O (pregnancy, birth, postpartum) and Z
(facts influencing the state of health and leading to the use of health
services) were excluded as they do not indicate diseases. Comorbidities
were identified during four quarters: the quarter before the first
documentation of the lung cancer diagnosis, the quarter in which the
lung cancer diagnosis was made and two quarters after the initial lung
cancer diagnosis (see Supplementary Table 5 for a thorough description of
all measures included). These four quarters are described in this paper as
patient-individual years. Comorbidities were only considered once within
the patient-individual year even if they were documented more than once.
The CCI was also calculated for the four patient-individual quarters and
includes 19 different diseases30. Each comorbid disease ranges from 1 to 6
points to summate an index value. The index value enables the division
into four prognostically significant categories (0, 1–2, 3–4, ≥5)31.
Accordingly, the annual mortality of category 0 is 12 and 85% for
category 5.
Individual ambulatory care physicians and their specialist area were
identified by the Lifelong Physician Identification Number. All outpatient
diagnoses contain the information in which physician documented the
outpatient diagnosis. For patients whose diagnosis of a concomitant
disease was documented by two different ambulatory care physicians in
the index quarter, both specialists were registered, since it is not possible
to distinguish who made the initial diagnosis. We included all relevant
specialists for the treatment of oncological diseases in the field of internal
medicine.
The German Medical Association defines the conditions under which
specialists in internal medicine (internists) and general medicine (general
practitioners) can acquire the specialist or specialization title32.
Additionally, patient’s age and the number of quarters with at least one
contact to a specific ambulatory care physician group were registered. Age
was calculated as the age on 31 of December in the previous year and as the
age on 31 December 2017 for the 5-year prevalence. Next, patients were
assigned to three age groups: <65, 65–85, and >85 years (Additional File 1).
To calculate the number of quarters with at least one contact to a specific
ambulatory care physician group, per patient, four individual quarters were
observed (patient-individual year). This means that the maximum number of
CQs to outpatient physicians is four. The same time frame was used to
calculate the average number of visits to ambulatory care physicians.
Data analysis
For the years 2013 to 2017, 5-year prevalence and 1-year prevalences of
lung cancer were calculated. Incidence for 2013 to 2017 was calculated
using 2012 as validation period. Prevalence and incidence crude rates were
adjusted by age and gender distribution of the German population in the
respective year or on 31.12.2017 for 5-year estimates. According to clinical
experience, the diagnosis of lung cancer generally becomes a permanent
diagnosis and no full recovery is possible. Permanent diagnoses are
available on a quarterly basis.
To describe the sociodemographic and clinical characteristics of incident
lung cancer patients, mean (M), standard deviation (SD), median (Md),
minimum (min) and maximum (max) were calculated for continuous
variables (definitions and description of all variables in Additional File 1).
For binary variables, absolute (n) and relative (%) frequencies of patients
were specified. Regional differences are presented stratified annually from
2013 to 2017 in order to observe changes over a period of 5 years. In this
context, a descriptive and non-standardized analysis of age and gender
distribution was performed. For descriptive and comparative purposes,
95% CIs are provided assuming a Poisson distribution. All statistical
analyses were conducted using Microsoft R Open 3.5.0.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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